Diagnostic Center | August 15, 2024
ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll
The clinical trial will be conducted at 19 sites with 10,335 participants across India
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
This project is supported by the Irish Government through IDA Ireland
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
Subscribe To Our Newsletter & Stay Updated
